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Abstract Anovelmulti-dose inhaler has been developed to closely approach the characteristics of an‘‘ideal’’ inhaler.
The newdevice,AirmaxTM, usesproprietary technologiesknown as the X-ACTTM systemto provide accurate and con-
sistent dosing and excellent lung depositionFeven at low inspiratory flow ratesFcombined with ease of use by the
patient.Dose delivery was close to label claim, with relative standard deviation of typically around 5% for through-life
emittedmass and around10% fordose per actuation.At a flowrate (60--70 l/min), which corresponds to 4 kPa pressure
drop across the device, themean fine particle (o5 mm) dose (FPD) from100, 200 and 400 mg strength budesonide Air-
maxTM was around 46, 98 and 244 mg, respectively. The mean FPD from 100 mg strength salbutamol AirmaxTM was
approximately 50 mg at the same flow rate. At 30 l/min, the delivered dose from AirmaxTM is over 85% label claimwith
fine particle fraction of over 35%.Performance was unaffected by shaking or orientation, provided the device was not
used completely upside down, andprimingwas not required.Therewas no change in dose contentuniformity and aero-
dynamic particle-size distribution after the deviceshavebeen storedunwrapped at 301C/60% RHupto 24 months. Air-
max is robust, portable and intuitive to use.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2002.1362, available online at http://www.idealibrary.comon
Keywords AirmaxTM; salbutamol; budesonide; inhalation therapy; dry powder inhalers.INTRODUCTION
Dry powder inhalers (DPIs) are breath-operated devices
and have been used as an alternative to pressurised me-
tered dose inhalers (pMDIs) for the delivery of drugs to
the lung.Without theuse of anypropellants,DPIs are en-
vironmentally friendly and do not require coordination
of inhalation and actuation. Single-dose DPIs such as the
Rotahaler (GSK) and Spinhaler (RPR) were introduced
approximately 30 years ago (1). In these inhalers, each
unit dose of drug is dispensed by piercing a gelatin cap-
sule containing the drug powder, normally a blend with
lactose. Since these devices have to be loaded with the
capsule prior to each usage, they are very inconvenient
to use and often pose di⁄culty for patients with acute
asthma attack. More recently, development has taken
place of devices holdingmultiple pre-metered unit doses
(Diskhaler and Diskuss, GSK), and reservoir-type de-
vices, where each dose is metered from bulk during useReceived 30October 2001, accepted in revised form 5 February 2002.
Correspondence should be addressed to: Xian-Ming Zeng, PhD,
Pulmonary Research andDevelopment, IVAXPharmaceutical U.K.Ltd,
Albert Basin,RoyalDocks,LondonE162QJ,U.K.Fax: +44 2075407757;
E-mail: xian-ming.zeng@ivax.co.uk(Turbuhalers, AstraZeneca and Clickhalers, Innovata
Biomed) (2).
Many authors have sought to identify the characteris-
tics of the ‘‘ideal’’ inhaler (3,4). An ‘‘ideal inhaler’’ should
not contain any propellants but is capable of delivering a
high portion of drug to the lung with minimal drug de-
position in the oropharynx. Dose delivery and aerody-
namic particle size of aerosolised drug should be
consistent and predictable, which is independent of in-
spiratory e¡ort and ambient humidity.The device should
be attractive, convenient, robust and intuitive to use.
The device shouldhave a dose indicator, both to aid com-
pliance and to providewarning that the inhaler is close to
empty. There should also be dosing feedback feature to
inform the patients that a dose has been taken.
No single inhaler in themarketmeets all these criteria
although two of themost sophisticatedmulti-doseDPI’s,
Diskuss and Turbuhalers reach di¡erent compromises
in approaching these goals.Therefore, a novelmulti-dose
inhaler has been developed tomore closely approach the
ideal characteristics described above. The new device,
AirmaxTM uses ‘‘Active Metering and Cyclone Separator
Technology’’, known as X-ACTTM system to provide ac-
curate and consistent dosing and to generate a high re-
spirable dose even at low inspiratory £ow rates. In this
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was assessed against the criteria of the ‘‘ideal inhaler’’
and compared with some commercial devices. Salbuta-
mol and budesonide were chosen since they represent
two major categories of anti-asthmatic drugs, namely
b2-receptor agonists and corticosteroids.Moreover, sal-
butamol as the sulphate is a hydrophilic compoundwhilst
budesonide is a hydrophobic material.The combined re-
sults fromboth compounds will give insight into the per-
formance of a wide range of active pharmaceutical
ingredients from AirmaxTM.
METHODS
Device design feature
AirmaxTM is a multi-dose reservoir device that delivers
up to 200 doses.The doseranges from anorder ofmicro-
grams to milligrams. The inhaler is speci¢cally designed
to have a shape similar to currentlymarketed pMDIs for
patient convenience (Fig. 1). Essentially, the inhaler com-
prises an assembly of the following main components:
upper case, metering spring, ¢lter, bellows, dose coun-
ter, slide-carrier, cyclone, mouthpiece and mouthpiece
cover.
The drug powder is contained in the hopper covered
by a ¢lter. The upper case, the top cover of the device
providesprotection to thepowder from the external en-
vironment.Themotive power to operate the AirmaxTMFIG. 1. A schematic diagram of the design features of Air-
maxTM.mechanism is derived from opening themouthpiece cov-
er by the patient. The metering spring is the source of
the power that compresses the bellows, which in turn
generates a uniform pressure over the powder blend.
The pressure will then force the powder to be metered
from the hopper to the dose cup locatedbelow the drug
reservoir.The slide-carrier holds the dose cup and trans-
fers the dose cup to the inhalation position once it is
loadedwith thepowder blend.On inhalation, allmetered
dose will be entrained into the air-stream and carried
into the cyclone where the drug particles are detached
from the carrier and dispersed into primary particles
that will reach the lung.The dose counter is ¢tted to in-
dicate thenumber of doses that are left inside the device.
After inhalation, the dose cup is transferred back tome-
tering position for the next cycle of operation.The inha-
lation sequence is completed by closing themouth piece
cover which provides additional protection to the device
from ambient humidity.
Formulation development
For administration via AirmaxTM, micronised drug (sal-
butamol and budesonide) was ¢rst mixed with coarse
lactose to prepare a homogeneous blend that was then
¢lled into the hopper of the device. The delivered dose
is altered by means of controlling either the active con-
centration of the blend or the size of the dose cup or a
combination of the two parameters to deliver a nominal
dose of 100mg of salbutamol, 100, 200 and 400mg of bu-
desonide.
Assessment of pharmaceutical performance
Emittedmass
The through-life emitted mass from AirmaxTM was as-
sessed gravimetrically using the emitted dose collector
system (EDCS, theTechnology Partnership).The perfor-
mance of AirmaxTM was also compared with that of a
conventional multi-dose dry powder inhaler (Pulmicort
Turbuhalers). For both inhalers, single dose was drawn
into a collection ¢lter at an air£ow rate of 60 l/min for
4 s.The increase in the weight of the ¢lter was taken to
represent themass delivery of each actuation.
AirmaxTM has also been tested using the automated
dose test machine (ADTM, theTechnology Partnership),
which measures unit dose drug delivery of the device
through life using an HPLC method. Devices containing
100 and 400mg budesonide per dose were tested, both
for 200 doses.
Dose content uniformity (DCU)
Doseper actuation (DPA) was testedusing conditions as
speci¢ed in European Pharmacopoeia (2000). Thus, ten
406 RESPIRATORYMEDICINEdoses, three atbeginning, fourmiddle and three at end of
device life, were ¢red separately into a Dose Uniformity
Sampling Apparatus (Copley,U.K.) at Q, a £ow rate that
corresponds to a pressure drop of 4kPa across the de-
vice (ca. 60 7^0 l/min). After 4 litres of air hadbeendrawn
through the device, the drug that was collected was re-
covered and analysed using a validated HPLC method.
Whilst DPA results are routinely assessed using Eur-
opean Pharmacopoeia (2000) speci¢cations for DCU,
some content uniformity results have been recalculated
as percentage of label claim and these results were ob-
tained from development, stability, clinical and scale-up
batches in order to best re£ect the true performance
of the product.
Aerodynamic particle-size distribution
This was assessed using a ¢ve-stage liquid impinger
(MSLI,Copley,UK) operated at the European Pharmaco-
poeia (2000) conditions.Ten doseswere actuated into an
MSLI, each drawn by 4 litres of air at Q.The drug depos-
ited in each stage of the impinger was recovered by
washing the stagewith suitable solvents and thewashing
solutionwas then assayed for drug concentration using a
validated HPLC method. The dose number was deter-
mined by sensitivity of the assay methods such that the
drug retained at the stage with minimal deposition
(usually stage 2 of the impinger) can be accurately mea-
sured.Each devicewas tested at the beginning and at the
end of device life.
Total dose recovery (TDR) was the sum of drug col-
lected from the induction port and all ¢ve stages of the
impinger. Fine particle dose (FPD) was de¢ned as the
dose of the aerosolised drug with particle sizeo5mm.
Fine particle fraction (FPF) was the percentage ratio of
FPD toTDR.Resultswere also expressed asmassmedian
aerodynamic diameter (MMAD) andgeometric standard
deviation (GSD) of the particles collected in the MSLI.
Inspiratory £owrates
To assess the variation in performance with £ow rates,
DPA and aerodynamic particle-size distribution from
AirmaxTM were assessed at 30, 60 and 90 l/min, the £ow
rates commonlyemployed to represent low,mediumand
high £ow rates achievable by patients. Testing was con-
ductedusing operational procedures similar to those de-
scribed above.
Storage stability
Extensive stability studies are being performed on these
productsunder InternationalConference onHarmonisa-
tion (ICH) conditions. Devices are stored at several or-
ientations, under various conditions including 251C/
60%, 301C/60% and 401C/75% RH, both in their ¢nal
packaged form and completely unpacked to mimic theconditions when the devices are used by patients. After
storage, devices were tested for pharmaceutical perfor-
mance, water content, degradation products andmicro-
bial quality.
ASSESSMENTOFDEVICEROBUSTNESS
Priming study
In this study, the need for priming AirmaxTM was investi-
gated in six randomly selected devices, three containing
100mg budesonide per dose and three containing 400mg
budesonide per dose. Each of the ¢rst six doses was col-
lected and the drug per actuation determined and com-
pared.
Shaking studies
For each of 50 actuations, themass of blend deliveredby
three devices ¢lled with100mg budesonide blend shaken
before each actuation was compared to a control. The
testwas repeatedusingdevices ¢lledwith100mg salbuta-
mol blend.Devices were shaken by holding the inhaler in
an upright position with the mouthpiece cover closed
and moving them up and down three times through
20 cm for thebudesonide devices, and ¢ve times through
30cm for the salbutamoldeviceswithin a period a period
of 4 s.The emittedmass of the blend was assessed using
themethod as speci¢ed above.
Orientation study
A study was conducted to investigate the e¡ect of
orientation of the device on drug delivery. In this test
the orientation of the device was varied during meter-
ing, but was kept upright for inhalation.The device used
was ¢lled with a blend of budesonide and lactose, with a
dose cup metering approximately 5mg of blend
per actuation. The dose was extracted at an air£ow of
60 l/min.
Drop test study
Five devices were dropped 1m onto concrete. Each de-
vicewas dropped a total of ¢ve times, once in each of ¢ve
di¡erent orientations (top, bottom, front, back and
side).The devices were then taken apart to assess their
condition.
RESULTS
Emittedmass
The through-life gravimetric emitted mass of AirmaxTM
200mg budesonide (n=2) was consistent with a mean of
5.09 and 5.02mg and relative standard deviations (RSD)
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FIG. 2. Acomparison of through-life emittedmass from a bu-
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FIG. 3. Through-life DPA from 100 and 400 mg budesonide
AirmaxTMinhalers.
SALBUTAMOLANDBUDESONIDE INANOVELINHALER 407of 5.8 and 4.7%, respectively. In contrast, mean emitted
mass of two Turbuhalers devices was 0.143mg
(RSD=22.9%) and 0.114mg (RSD=23.9%).For the 400mgde-
vices, the emitted mass of two AirmaxTM inhalers was
4.38mg (RSD=4.9%) and 4.66mg (RSD=5.8%). The corre-
sponding results for two Turbuhalers devices were
0.299mg (RSD=18.3%) and 0.227mg (RSD=17.9%). Figure 2
shows typical mass-delivery pro¢les from the AirmaxTM
and Turbuhalers.Clearly, the consistency of the emitted
mass is greater with AirmaxTM than with the Turbuha-
lers.
THROUGH-LIFEDOSEDELIVERY
The AirmaxTM inhalers produced through-life mean
DPAs of102.7 and 398.5mg with RSDs of 3.72 and 2.96%
for a 100 and 400mg device, respectively. There is no
change in dose delivery throughout device life (Fig. 3).
DOSECONTENTUNIFORMITY
The DPA results of 35 devices from ¢ve batches of salbu-
tamol AirmaxTM, two batches of budesonide100mg, ¢ve
batches of budesonide 200mg and sevenbatches of bude-
sonide 400mg were recalculated and then combined to
give the distribution pattern shown in Fig. 4.Three hun-
dred and twenty-six DPAs (93.1%) were within 80 1^20%
LC and 340 DPAs (97.1%) within 75 1^25% LC. All but one
DPAwerewithin 65 1^35% LC. All individual deviceswere
shown to produce mean DPA within 85 1^15% LC. The
overallmeanwas 97% LCwith RSD of12%.
Aerodynamic particle-size distribution
Fineparticle fractionwasmeasuredbetween 47 and 64%
for all three strengths of budesonide, and there was no
di¡erence in the performance at the start and end of de-
vice life (Table 1). The MMAD varied between 2.0 and
2.3mm and GSD between 1.7 and 2.2. Total dose recov-
ery was close to label claim in all cases throughout the
nominal number of actuations.
Flowdependence
Figure 5 shows that, although there is an increase inboth
DPA and FPF by increasing the £ow rates, the delivered
dose fromAirmaxTM is over 85% label claim and FPF over
35% at a £ow rate as low as 30 l/min.
Storage stability
There is no change in dose delivery and ¢neparticle dose
from salbutamol AirmaxTM after storage unprotected at
301C/60% RH for over 24 months, and storage orienta-
tion does not a¡ect the performance of the results(Fig. 6).Therewas no change inwater content and degra-
dation products.
Priming study
Actuation1^6 did not di¡er with respect to drug recov-
ery in any of the six devices tested (% RSD varying from
4.9 to19.8%). It is therefore concluded that a priming step
is not required for AirmaxTM.
Shaking studies
No signi¢cant di¡erences were found for either the bu-
desonide or salbutamolproducts for themean and RSD of
the emitted mass between the shaken devices and the
controls. For example, the budesonide control device
produced a mean emittedmass of 2.69mg, whichwas si-
milar to those of the shaken devices (2.56 2^.75mg).The
RSDs of the shaken devices (3.5 5^.2%)were slightly higher
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FIG. 4. Dose distribution fromthe salbutamol andbudesonide AirmaxTM (dose number = 350).
TABLE 1. Aerodynamic particle-size distribution of budesonide from AirmaxTM measured by anMSLI at Q
Test parameters Device strength/no of actuations (device no.)
100 mg/200 (n=3) 200 mg/100 (n=3) 400 mg/50 (n=3)
Startof inhaler:
Total dose recovery (TDR mg) 92.3 (86.8 9^6.6) 192.6 (188.5 1^98.3) 381.2 (371.3 3^87.1)
MMAD (mm) 2.2 (2.1 2^.2) 2.3 (2.2 2^.3) 2.2 (2.1 2^.2)
GSD 2.1 (2.1 2^.1) 2.1 (2.0 2^.1) 1.7 (1.1 2^.0)
Fine particle dose (mg) 47 (44 5^1) 95 (90 1^02) 243 (235 2^49)
Fine particle fraction (% TDR) 51 (49 5^3) 49 (47 5^1) 64 (63 6^4)
End of inhaler
Total dose recovery (mg) 89.6 (87.6 9^1.6) 193.0 (191.1 1^96.2) 402.4 (394.8 4^15.1)
MMAD (mm) 2.1 (2.1 2^.2) 2.3 (2.1 2^.4) 2.2 (2.2 2^.3)
GSD 2.0 (2.0 2^.1) 2.0 (1.9 2^.1) 2.0 (2.0 2^.0)
Fine particle dose (mg) 46 (45 4^6) 101 (98 1^07) 245 (235 2^54)
Fine particle fraction (% TDR) 51 (51 5^1) 52 (51 5^5) 61 (59 6^4)
408 RESPIRATORYMEDICINEthan the control device (3.0%).For salbutamol AirmaxTM
devices, the control device gave a mean emittedmass of
2.34mg, which was again similar to those of the shaken
devices (2.41 2^.59mg). The RSDs of all the three shaken
devices were below 5%.Therefore, shaking does not af-
fect dose delivery from AirmaxTM devices.
Orientation study
Theperformance ofAirmaxTMwas consistent atorienta-
tions up to 901 in either direction, i.e. with the device
tilted forwards or backwards horizontally. It can be seen
from Table 2, that the mean emitted mass varied be-
tween orientations by a maximum of 4.8%, and the RSDwas consistently below 5%, unless the device was held
completely upside down. In this orientation, the device
did not performwell, and although there was still some
delivery, this haddropped to aboutone-third of the nom-
inal.
Drop test study
Therewas no damage to the internal components or ex-
ternal case of any of the units following drop test. The
mouthpiece covers showed some signs of cosmetic da-
mage.Three samples dropped on the bottom-down or-
ientation displayed white stress marks around the hinge
legs, and a fourth had a ¢ne crack in the material
SALBUTAMOLANDBUDESONIDE INANOVELINHALER 409between the hinge legs but this did not a¡ect the
operation. In conclusion, therefore, all devices were fully
functional following drop testing from di¡erent orienta-
tions.0
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TABLE 2. Emittedmass of budesonide AirmaxTMdevices after a
Orientationa (deg) Shotnumbers
Vertical 1 2^0
+45 21 3^0
+90 51 6^0
45 31 4^0
90 41 5^0
180 (upside down) 61 7^0
aApositive signrefers to leaning forwards and a negative signtDISCUSSION
The AirmaxTM inhaler embodies technology speci¢cally
designed to provide improved performance relative to
competitor devices, and to enable it to more closely ap-
proach the performance of the ‘‘ideal’’ inhaler.
The active metering principle is used to achieve pre-
cise, repeatable dose delivery insensitive to orientation
or prior shaking. In testing, AirmaxTM demonstrated
good dose uniformity, and the consistency of emitted
mass is re£ected in repeatable unit dose drug delivery.
Drug delivery from AirmaxTM is close to the label claim
and theperformance ismaintained throughout life. Shak-
ing the device has no signi¢cant e¡ect on dose delivery
and dose uniformity is una¡ected by device orientation,
provided AirmaxTM is not used upside down. AirmaxTM
has been designed to have an outline familiar to users of
a pMDI, and to be used in the same orientation. Patients
are aware that a pMDImustbeusedupright, andhence it
is unlikely that the AirmaxTM device would be used in-
verted. Priming before use is not required. The consis-
tency of emitted mass under a variety of conditions
would lead one to expect consistent performance in pa-
tientuse, where the devicemaybe subject to a variety of
treatment between doses.
The second element of the technology is the cyclone
separator.This ensures that theprecise dose is e⁄ciently
dispersed to provide a high lung delivery. When mea-
sured at £ow rate corresponding to 4kPa pressure drop
across the device, both salbutamol and budesonide Air-
maxTM devices gave the FPF of approximately 50% or
higher and the MMAD between 2.0 and 2.3mg, and this
performance was maintained throughout the life of the
product.
Nearly all currently available DPIs rely on the patients’
inspiratory e¡ort for the delivery and aerosolisation of
the medicament and hence, increasing inspiratory £ow
rate almost always results in an increase in both the de-
livereddose and ¢neparticle fraction of the drug.For ex-
ample, a threefold increase in the FPD from the
Turbuhalers has been reported by increasing the £ow
rate from 30 to 60 l/min (5).The delivered dose of salbu-ctuation atdi¡erentorientations
Mean emittedmass (mg) RSD (%)
5.00 8.5
5.03 3.9
5.24 3.6
5.12 2.7
5.08 3.8
1.66 42.5
o leaningbackwards.
410 RESPIRATORYMEDICINEtamol from all three commercial devices, namely the
Diskuss, Diskhaler and Turbuhalers was also shown to
increase from 30 to 90 l/min (6).The delivered dose from
the AirmaxTM is within 85 1^15% LC at a £ow rate be-
tween 30 and 90 l/min, suggesting that the AirmaxTM is
relatively independent of inspiratory £ow rate.The dose
accuracy and consistencyofAirmaxTM are comparable to
those reported for Buventol Easyhaler (7).
The performance of budesonide AirmaxTM at 30, 50,
70 and 90 l/min has also been investigated.The data ob-
tained indicate that evenwhen a £ow rate as low as 30 l/
min is applied, values of ca. 30mg were obtained for the
¢neparticle dose for the100mgproduct and of ca.100mg
for the 400mg product.
The inspiratory £ow rate achievable by asthmatic pa-
tients from AirmaxTM can be estimated from that re-
ported forTurbuhalers since these devices have similar
air resistance, in the range of 0.09^0.10 (cmH2O)
0.5
min.l1. It has been reported that 98% of asthmatic pa-
tients with acute asthma were able to generate inspira-
tory £ow rate of 430 l/min, which is considered to be
adequate for use of Turbuhalers (8). In another study
(9), all inspiratory £ow recordings, achieved by 30 stable
asthmatic patients onmaintenance doses of inhaled ster-
oids viaTurbuhalers, were above 30 l/min with 13 of the
5248 recordings o 40 l/min. The individual mean £ow
rates were in the range 55 9^5 l/min. A separate study
also showed that an inspiratory £ow rate of 30 l/min can
be generated from theTurbuhalers by virtually all chil-
dren agedX6 years, by 42 of 57 childreno6 years (10).
The air resistance of AirmaxTM is ca. 0.09
(cmH2O)
0.5min.l1, which is slightly less than the value
of 0.100 (cmH2O)
0.5min.l1 for theTurbuhalers (11).The
same inspiratory e¡ort will generate slightly higher £ow
rate from the AirmaxTM than from the Turbuhalers.
Therefore, a £ow rate of X30 l/min is easily achievable
from the AirmaxTMby asthmatic and paediatric patients.
Moisture uptake generally has a detrimental e¡ect on
the performance of dry powder formulation for inhala-
tion. Even a very small amount of moisture uptake will
greatly reduce the ¢ne particle fraction/dose of drug
due to a substantial increase in the inter-particulate
forces within the powder. There are two major ap-
proaches to protect the powder contained in a dry pow-
der inhaler from external moisture. The ¢rst is to use
individually sealed doses which have been measured out
by the factories using either capsules (Rotacaps) andblis-
ters (Diskuss/Diskhaler). The second is to protect the
powder reservoir or the entire device frommoisture by
means of either foil-wrapping or inclusion of a desiccant.
It canbe seen from these results that AirmaxTM provides
adequate protection to salbutamol sulphate frommoist-
ureuptake. Such a level of protection canbe expected to
be su⁄cient to protectmore hydrophobic drugs such as
budesonide. This has indeed been proven true since no
change was observed in pharmaceutical performance ofbudesonide AirmaxTM after storage at conditions of
401C/75% and 301C/60% RH for a period of 12 months
(data not shown).
Apart from delivering a good technical performance,
it is important that an inhaler is attractive, convenient,
robust and as simple and foolproof inuse aspossible. Air-
maxTM has been designed to have a familiar shape, not
unlike the pMDI that most patients will have used. It is
compact, and simple and easy to operate: opening the
mouthpiece cover is all that is necessary to prepare a
dose for inhalation, and after taking the dose closing
the dust cover againmakes the device ready for the next
use. The most convenient way to open the mouthpiece
cover and inhale through the device is to hold it upright,
making it intuitive to use.The sweetness of the excipient
lactose will inform the patient that a dose has been ta-
ken. A dose counter with a generously sized display pro-
vides a clear and precise indication of the number of
doses remaining and gives extra warning as the inhaler
approaches empty. All of these functions are operated
from the movement of the mouthpiece cover by a me-
chanical sequence controller inside the device, which co-
ordinatesmeteringof the dose, transfer to the inhalation
position and advancement of the dose counter. Testing
demonstrated that the sequence controller is una¡ected
byoperation to ¢ve times thenormal device life, and that
the device is robust andresistant to droppingonto a hard
£oor.
In conclusion, a novel multi-dose dry powder inhaler
has been developed to more closely approach the char-
acteristics described in the literature of an‘‘ideal’’ inhaler.
The new device, AirmaxTM is capable of delivering pre-
cise and consistent dose of drugs throughout device life.
Over half of the delivered dose from the device has an
aerodynamic particle size suitable for lung delivery. Air-
maxTM is relatively less dependent upon inhalation £ow
rates in terms of performances in comparison to com-
mercial devices. It delivers a su⁄ciently high ¢ne particle
dose at a £owrate as low as 30 l/min. AirmaxTM provides
adequate protection to the drug-containing powder
from external humidity such that no change was ob-
served in all the performance parameters after storage
of the devices unwrapped at elevated conditions up to
24 months. It has a dose counter and a dosing feedback
feature. It is intuitive to use, portable, robust and have a
familiar and attractive shape. Therefore, the AirmaxTM
possesses nearly all the criteria required for the‘‘ideal in-
haler’’, and it is expected that these in vitro results will be
re£ected in an excellent performance in patient use.
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